Abstract
Background: There is no curative treatment for Alzheimer’s disease (AD). Ginseng is widely used in the treatment of AD in Asian countries. Objective: To evaluate the effectiveness and safety of ginseng for AD. Methods: We searched seven main databases for randomized clinical trials (RCTs) on ginseng for AD from their inception to December 2014. The Cochrane risk of bias tool was used to assess the methodological quality. We used RevMan 5.2 to synthesize the results. Results: Four RCTs involving 259 participants were identified for this systematic review. The methodological quality of included studies was not promising. All comparisons were made between combined treatment (ginseng plus conventional treatment) versus conventional treatment. The results of meta-analyses and several individual studies showed that the effectiveness of combined treatment was inconsistent as measured by MMSE, ADAS-cog, ADAS-noncog, and CDR. No studies reported the outcomes of quality of life (QoL). The current data did not report serious adverse events. Conclusion: This review showed that the effects of ginseng on AD were still inconclusive. The main limitations of the available studies were small sample sizes, poor methodological qualities and no placebo controls. Larger, well-designed studies are needed to test the effect of ginseng on AD in the future.
Keywords: Alzheimer’s disease, Ginseng, Ginsenoside, Meta-analysis, Randomized controlled trial, Systematic review.
Current Topics in Medicinal Chemistry
Title:Ginseng for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Volume: 16 Issue: 5
Author(s): Yuyi Wang, Guoyan Yang, Juan Gong, Fang Lu, Qingchun Diao, Jin Sun, Kang Zhang, Jinzhou Tian and Jianping Liu
Affiliation:
Keywords: Alzheimer’s disease, Ginseng, Ginsenoside, Meta-analysis, Randomized controlled trial, Systematic review.
Abstract: Background: There is no curative treatment for Alzheimer’s disease (AD). Ginseng is widely used in the treatment of AD in Asian countries. Objective: To evaluate the effectiveness and safety of ginseng for AD. Methods: We searched seven main databases for randomized clinical trials (RCTs) on ginseng for AD from their inception to December 2014. The Cochrane risk of bias tool was used to assess the methodological quality. We used RevMan 5.2 to synthesize the results. Results: Four RCTs involving 259 participants were identified for this systematic review. The methodological quality of included studies was not promising. All comparisons were made between combined treatment (ginseng plus conventional treatment) versus conventional treatment. The results of meta-analyses and several individual studies showed that the effectiveness of combined treatment was inconsistent as measured by MMSE, ADAS-cog, ADAS-noncog, and CDR. No studies reported the outcomes of quality of life (QoL). The current data did not report serious adverse events. Conclusion: This review showed that the effects of ginseng on AD were still inconclusive. The main limitations of the available studies were small sample sizes, poor methodological qualities and no placebo controls. Larger, well-designed studies are needed to test the effect of ginseng on AD in the future.
Export Options
About this article
Cite this article as:
Wang Yuyi, Yang Guoyan, Gong Juan, Lu Fang, Diao Qingchun, Sun Jin, Zhang Kang, Tian Jinzhou and Liu Jianping, Ginseng for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Current Topics in Medicinal Chemistry 2016; 16 (5) . https://dx.doi.org/10.2174/1568026615666150813143753
DOI https://dx.doi.org/10.2174/1568026615666150813143753 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: The Complex and Multifactorial Nature of Alzheimers Disease (Guest Editors: Karim Alkadhi and Jason Eriksen)]
Current Neuropharmacology Free Radicals in Diseases and Potential Role of Phytoconstituents-A Cause with Emerging Importance
Current Chemical Biology Melatonin as Antioxidant Under Pathological Processes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Raf Inhibitors as Therapeutic Agents Against Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Lipid Nanoformulations in the Treatment of Neuropsychiatric Diseases: An Approach to Overcome the Blood Brain Barrier
Current Drug Metabolism Heat Shock Proteins: Therapeutic Drug Targets for Chronic Neurodegeneration?
Current Pharmaceutical Biotechnology Oligodendrocyte Development and Myelination in Neurodevelopment: Molecular Mechanisms in Health and Disease
Current Pharmaceutical Design Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG
Current Vascular Pharmacology Changing the Course of Alzheimers Disease: Emerging Disease Modifying Therapies
Current Psychiatry Reviews Tailored Multi-Target Agents. Applications and Design Considerations
Current Pharmaceutical Design Acetylcholinesterase (AChE) - Amyloid-β-Peptide Complexes in Alzheimers Disease. The Wnt Signaling Pathway
Current Alzheimer Research EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes
Current Neurovascular Research Donepezil Derivatives Targeting Amyloid-β Cascade in Alzheimer's Disease
Current Alzheimer Research Alzheimer's Disease and the Routine Clinical Use of CSF Biomarkers
CNS & Neurological Disorders - Drug Targets Brain Network Connectivity Mediates Education-related Cognitive Performance in Healthy Elderly Adults
Current Alzheimer Research Adrenomedullin and Oxidative Stress in Vascular Damage and Metabolic Disease
Current Hypertension Reviews Drugs and Foods for Chronic Subclinical Inflammation in Humans
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Current Therapeutic Strategy in the Nasal Delivery of Insulin: Recent Advances and Future Directions
Current Pharmaceutical Biotechnology Inflammatory Cytokines in Acute Ischemic Stroke
Current Pharmaceutical Design Natural Animal Models of Neurodegenerative Protein Misfolding Diseases
Current Pharmaceutical Design